IDEXX Laboratories, Inc. (NASDAQ:IDXX) Director M Anne Szostak sold 5,906 shares of IDEXX Laboratories stock in a transaction that occurred on Thursday, February 14th. The shares were sold at an average price of $208.96, for a total transaction of $1,234,117.76. Following the completion of the transaction, the director now directly owns 6,490 shares in the company, valued at approximately $1,356,150.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of IDEXX Laboratories stock traded up $1.06 during midday trading on Tuesday, hitting $211.32. The company had a trading volume of 484,100 shares, compared to its average volume of 552,948. The company has a market cap of $18.13 billion, a price-to-earnings ratio of 49.61 and a beta of 1.02. IDEXX Laboratories, Inc. has a 1-year low of $176.11 and a 1-year high of $256.22.
IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Friday, February 1st. The company reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.08. The business had revenue of $549.39 million for the quarter, compared to the consensus estimate of $546.04 million. IDEXX Laboratories had a net margin of 17.03% and a negative return on equity of 1,501.97%. IDEXX Laboratories’s quarterly revenue was up 8.5% on a year-over-year basis. During the same quarter last year, the company posted $0.43 earnings per share. On average, analysts anticipate that IDEXX Laboratories, Inc. will post 4.69 earnings per share for the current year.
Several institutional investors have recently made changes to their positions in IDXX. Pearl River Capital LLC acquired a new stake in IDEXX Laboratories during the fourth quarter worth $28,000. Sontag Advisory LLC acquired a new stake in IDEXX Laboratories during the fourth quarter worth $79,000. Quantamental Technologies LLC acquired a new stake in IDEXX Laboratories during the fourth quarter worth $92,000. Migdal Insurance & Financial Holdings Ltd. boosted its stake in IDEXX Laboratories by 144.3% during the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 618 shares of the company’s stock worth $154,000 after buying an additional 365 shares in the last quarter. Finally, Ipswich Investment Management Co. Inc. acquired a new stake in IDEXX Laboratories during the fourth quarter worth $124,000. Institutional investors and hedge funds own 87.41% of the company’s stock.
Several brokerages have recently issued reports on IDXX. Bank of America lowered their price objective on shares of IDEXX Laboratories from $275.00 to $235.00 and set a “buy” rating on the stock in a research note on Friday, November 2nd. Canaccord Genuity lowered their price objective on shares of IDEXX Laboratories from $270.00 to $250.00 and set a “buy” rating on the stock in a research note on Monday, November 5th. Zacks Investment Research upgraded shares of IDEXX Laboratories from a “hold” rating to a “strong-buy” rating and set a $236.00 price objective on the stock in a research note on Monday, February 4th. Finally, BidaskClub upgraded shares of IDEXX Laboratories from a “sell” rating to a “hold” rating in a research note on Thursday, January 24th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $246.00.
WARNING: “IDEXX Laboratories, Inc. (IDXX) Director Sells $1,234,117.76 in Stock” was reported by Macon Daily and is the property of of Macon Daily. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://macondaily.com/2019/02/19/idexx-laboratories-inc-idxx-director-sells-1234117-76-in-stock.html.
About IDEXX Laboratories
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
Recommended Story: How interest rates affect municipal bond prices
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.